ArticleCancer medicine2021

Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non-small-cell lung cancer harboring EGFR mutations: Results from a real-world study in South Korea.

Taeyun Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.